Clinical Focus ›› 2022, Vol. 37 ›› Issue (1): 92-96.doi: 10.3969/j.issn.1004-583X.2022.01.018
-
Received:2021-09-01Online:2022-01-20Published:2022-01-20
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.01.018
| [1] |
Chuang YW, Yu MC, Lin CLY,, et al. Risk of peripheral arterial occlusive disease in patients with rheumatoid arthritis. A nationwide population-based cohort study[J]. Thromb Haemost, 2016, 115(2):439-445.
doi: 10.1160/th15-07-0600 URL |
| [2] |
Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease[J]. Ann Rheum Dis, 2011, 70(3):482-487.
doi: 10.1136/ard.2010.135871 pmid: 21216812 |
| [3] |
Wu MF, Xu KZ, Guo YG, et al. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives[J]. Cardiovasc Drugs Ther, 2019, 33(6):739-748.
doi: 10.1007/s10557-019-06906-9 pmid: 31655942 |
| [4] |
Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: A narrative review of risk factors, cardiovascular risk assessment and treatment[J]. BMC Rheumatol, 2018, 2:10.
doi: 10.1186/s41927-018-0014-y URL |
| [5] | Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: The role of inflammation, drugs, lifestyle and genetic factors[J]. Curr Vasc Pharmaco, 2010, 8(3):301-326. |
| [6] | Yoshinaga R, Doi Y, Ayukawa K, et al. High-sensitivity C reactive protein as a predictor of inhospital mortality in patients with cardiovascular disease at an emergency department: A retrospective cohort study[J]. BMJ Open, 2017, 7(10):e015112. |
| [7] |
El Bakry SA, Fayez D, Morad CS, et al. Ischemic heart disease and rheumatoid arthritis: Do inflammatory cytokines have a role[J]. Cytokine, 2017, 96:228-233.
doi: 10.1016/j.cyto.2017.04.026 URL |
| [8] | Provan SA, Berg IJ, Hammer HB, et al. The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: A 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tociliziumab[J]. PLoS One, 2015, 10(6):e0130709. |
| [9] |
Arts EE, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis[J]. Ann Rheum Dis, 2015, 74(4):668-674.
doi: 10.1136/annrheumdis-2013-204024 pmid: 24389293 |
| [10] |
Gossec L, Salejan F, Nataf H, et al. Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: An observational study of 110 rheumatoid arthritis patients[J]. Arthritis Care Res (Hoboken), 2013, 65(5):712-717.
doi: 10.1002/acr.21935 pmid: 23589412 |
| [11] |
Arida A, Protogerou AD, Kitas GD, et al. Systemic Inflammatory response and atherosclerosis: The paradigm of chronic inflammatory rheumatic diseases[J]. Int J Mol Sci, 2018, 19(7):1890.
doi: 10.3390/ijms19071890 URL |
| [12] | Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases[J]. PLoS One, 2010, 5(12):e14328. |
| [13] |
Guin A, Sinhamahapatra P, Misra S, et al. Incidence and effect of insulin resistance on progression of atherosclerosis in rheumatoid arthritis patients of long disease duration[J]. Biomed J, 2019, 42(6):394-402.
doi: 10.1016/j.bj.2019.01.007 URL |
| [14] |
Zeisbrich M, Yanes RE, Zhang H, et al. Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation[J]. Ann Rheum Dis, 2018, 77(7):1053-1062.
doi: 10.1136/annrheumdis-2017-212647 pmid: 29431119 |
| [15] |
Semb AG, Kvien TK, Aastveit AH, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study[J]. Ann Rheum Dis, 2010, 69(11):1996-2001.
doi: 10.1136/ard.2009.126128 pmid: 20551156 |
| [16] |
Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease[J]. Ann Rheum Dis, 2011, 70(3):482-487.
doi: 10.1136/ard.2010.135871 pmid: 21216812 |
| [17] |
Giles JT, Wasko MCM, Chung CP, et al. Exploring the lipid paradox theory in rheumatoid arthritis: Associations of low circulating low-density lipoprotein concentration with subclinical coronary atherosclerosis[J]. Arthritis Rheumatol, 2019, 71(9):1426-1436.
doi: 10.1002/art.40889 |
| [18] |
Lubrano V, Gabriele M, Puntoni MR, et al. Relationship among IL-6, LDL cholesterol and lipid peroxidation[J]. Cell Mol Biol Lett, 2015, 20(2):310-322.
doi: 10.1515/cmble-2015-0020 pmid: 26204410 |
| [19] |
Strang AC, Bisoendial RJ, Kootte RS, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis[J]. Atherosclerosis, 2013, 229(1):174-181.
doi: 10.1016/j.atherosclerosis.2013.04.031 pmid: 23746537 |
| [20] |
Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib[J]. Arthritis Rheumatol, 2015, 67(3):616-625.
doi: 10.1002/art.38974 URL |
| [21] |
Robertson J, Porter D, Sattar N, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synjournal: A cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis[J]. Ann Rheum Dis, 2017, 76(11):1949-1952.
doi: 10.1136/annrheumdis-2017-211708 pmid: 28916714 |
| [22] |
Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis[J]. J Cell Mol Med, 2016, 20(1):17-28.
doi: 10.1111/jcmm.12689 pmid: 26493158 |
| [23] |
Hu J, Xi D, Zhao J, et al. High-density Lipoprotein and Inflammation and Its Significance to Atherosclerosis[J]. Am J Med Sci, 2016, 352(4):408-415.
doi: 10.1016/j.amjms.2016.06.014 URL |
| [24] |
Jia C, Anderson JLC, Gruppen EG, et al. High-density lipoprotein anti-inflammatory capacity and incident cardiovascular events[J]. Circulation, 2021, 143(20):1935-1945.
doi: 10.1161/CIRCULATIONAHA.120.050808 URL |
| [25] |
Ormseth MJ, Yancey PG, Solus JF, et al. Effect of drug therapy on net cholesterol efflux capacity of high-density lipoprotein-enriched serum in rheumatoid arthritis[J]. Arthritis Rheumatol, 2016, 68(9):2099-2105.
doi: 10.1002/art.39675 URL |
| [26] |
Chang TI, Streja E, Moradi H. Could high-density lipoprotein cholesterol predict increased cardiovascular risk?[J]. Curr Opin Endocrinol Diabetes Obes, 2017, 24(2):140-147.
doi: 10.1097/MED.0000000000000318 pmid: 28099207 |
| [27] |
Bassu S, Zinellu A, Sotgia S, et al. Oxidative stress biomarkers and peripheral endothelial dysfunction in rheumatoid arthritis: A monocentric cross-sectional case-control study[J]. Molecules, 2020, 25(17):3855.
doi: 10.3390/molecules25173855 URL |
| [28] |
ZMacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: Fuelling the fire of atherosclerosis or therapeutic extinguishers[J]. Int J Mol Sci, 2021, 22(14):7622.
doi: 10.3390/ijms22147622 URL |
| [29] |
Hafström I, Rohani M, Deneberg S, et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis-a randomized study[J]. J Rheumatol, 2007, 34(9):1810-1816.
pmid: 17696277 |
| [30] |
Restrepo JF, Del Rincon I, Molina E, et al. Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients[J]. J Clin Rheumatol, 2017, 23(3):144-148.
doi: 10.1097/RHU.0000000000000502 pmid: 28277344 |
| [31] |
Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages[J]. Arthritis Rheum, 2008, 58(12):3675-3683.
doi: 10.1002/art.v58:12 URL |
| [32] |
Johnson TM, Sayles HR, Baker JF, et al. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis[J]. Ann Rheum Dis, 2021, 80(11):1385-1392.
doi: 10.1136/annrheumdis-2021-220125 URL |
| [33] |
Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-α agents-Comparison among therapeutic TNF-α antagonists[J]. Cytokine, 2018, 101:56-63.
doi: 10.1016/j.cyto.2016.08.014 URL |
| [34] |
Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance[J]. Arthritis Res Ther, 2012, 14(3):R141.
doi: 10.1186/ar3874 URL |
| [35] |
Ursini F, Leporini C, Bene F, et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: A systematic review and meta-analysis[J]. Sci Rep, 2017, 7(1):5346.
doi: 10.1038/s41598-017-05759-2 URL |
| [36] |
Corrado A, Colia R, Rotondo C, et al. Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-α[J]. Curr Med Res Opin, 2019, 35(12):2197-2205.
doi: 10.1080/03007995.2019.1654988 URL |
| [37] |
Popa C, van Tits LJ, Barrera P, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients[J]. Ann Rheum Dis, 2009, 68(6):868-872.
doi: 10.1136/ard.2008.092171 pmid: 18635596 |
| [38] |
Veldhuijzen van Zanten JJCS, Sandoo A, Metsios GS, et al. Comparison of the effects of exercise and anti-TNF treatment on cardiovascular health in rheumatoid arthritis: Results from two controlled trials[J]. Rheumatol Int, 2019, 39(2):219-225.
doi: 10.1007/s00296-018-4183-1 pmid: 30421104 |
| [39] |
Hassan S, Milman U, Feld J, Eder L, et al. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: An analytical cohort study[J]. Arthritis Res Ther, 2016, 18(1):261.
pmid: 27832797 |
| [40] |
Végh E, Kerekes G, Pusztai A, et al. Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis[J]. Rheumatol Int, 2020, 40(3):427-436.
doi: 10.1007/s00296-019-04497-0 URL |
| [41] | Cacciapaglia F, Anelli MG, Rinaldi A, et al. Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment[J]. Mediators Inflamm, 2018, 2018:2453265. |
| [42] | Popkova TV, Novikova DS, Nasonov EL. Interleukin-6 inhibition and cardiovascular disease in patients with rheumatoid arthritis[J]. Ter Arkh, 2016, 88(5):93-101. |
| [43] |
Genovese MC, Kremer JM, van Vollenhoven RF, et al. Transaminase levels and hepatic events during tocilizumab treatment: Pooled analysis of long-term clinical trial safety data in rheumatoid arthritis[J]. Arthritis Rheumatol, 2017, 69(9):1751-1761.
doi: 10.1002/art.40176 URL |
| [44] |
Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials[J]. Arthritis Res Ther, 2011, 13(5):R141.
doi: 10.1186/ar3455 URL |
| [45] |
Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis[J]. N Engl J Med, 2012, 367(6):495-507.
doi: 10.1056/NEJMoa1109071 URL |
| [46] |
Kume K, Amano K, Yamada S, et al. Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: A cohort study[J]. Rheumatol Int, 2017, 37(12):2079-2085.
doi: 10.1007/s00296-017-3844-9 URL |
| [1] | . [J]. Clinical Focus, 2023, 38(8): 753-756. |
| [2] | . [J]. Clinical Focus, 2023, 38(7): 663-667. |
| [3] | . [J]. Clinical Focus, 2023, 38(3): 279-284. |
| [4] | Zhang Yueyue, Xie Meifang, Sun Gen. Rheumatoid arthritis complicated with T-cell large granular lymphocytic leukemia: A case report and literature review [J]. Clinical Focus, 2022, 37(8): 728-732. |
| [5] | Hu Fangfang, Zhong Shiling, Di Yazhen, Wu Ling. Vascular endothelial function of juvenile idiopathic arthritis in pediatric patients: A systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(3): 204-210. |
| [6] | Lin Changyi, Song Minghui, Wu Peicheng. Difference between remitting seronegative symmetrical synovitis with pitting edema syndrome and seronegative rheumatoid arthritis [J]. Clinical Focus, 2022, 37(3): 262-265. |
| [7] | . [J]. Clinical Focus, 2022, 37(2): 188-192. |
| [8] | Liu Ziyi, Wang Jibo. Analysis of clinical characteristics and related factors of rheumatoid arthritis complicated with malignant tumors in patients [J]. Clinical Focus, 2021, 36(3): 246-250. |
| [9] | . [J]. Clinical Focus, 2021, 36(1): 75-79. |
| [10] | Chen Wenyu, Wang Juanjuan, Wang Zhiming. Clinical feature of pleural effusion in 78 patients with rheumatoid arthritis [J]. Clinical Focus, 2016, 31(2): 214-217. |
| [11] | Xie Qingyun, Wei Meng, Fu Peiliang, Sun Jiuyi, Qian Qirong. Association study between single nucleotide polymorphisms of interleukin 23 receptor and rheumatoid arthritis [J]. Clinical Focus, 2016, 31(1): 40-44. |
| [12] | Wang Lei;Zhang Guimin;Li Li;Yu Zhibo;Yan Yonglong;Zhang Fengxiao;Sun Lijun. Application of high frequency energy Doppler ultrasound in monitoring of rheumatoid arthritis treatment [J]. Clinical Focus, 2015, 30(12): 1405-1409. |
| [13] | . [J]. Clinical Focus, 2015, 30(12): 1429-1.43014e+007. |
| [14] | Luo Hong;Chen Yanfei. Expression of interleukin-1β in platelet of patients with rheumatoid arthritis [J]. Clinical Focus, 2015, 30(8): 903-905. |
| [15] | Xie Qingyun;Wei Meng;Wang Tao;Cheng Yue;Zhu Changliang. Lipid profile in active rheumatoid arthritis and disease activity correlation [J]. Clinical Focus, 2015, 30(8): 906-908914. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||